SUBSCRIBE
SUBSCRIBE

Astria Therapeutics

NEWS
Business
BioSpace Movers & Shakers: Astria, Apertura, CytoDyn, IN8bio & More Make Big Moves
New leaders and top executive roles were selected to guide biopharma and life science companies from Apertura Gene Therapy to CytoDyn, Vaccentis AG, Suvoda LLC, IN8bio and more.
July 14, 2022
 · 
9 min read
 · 
Alex Keown
JOBS
IN THE PRESS
Press Releases
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
December 11, 2024
 · 
10 min read
Press Releases
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
December 10, 2024
 · 
6 min read
Press Releases
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 3, 2024
December 4, 2024
 · 
1 min read
Press Releases
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 14, 2024
 · 
13 min read
Press Releases
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
November 13, 2024
 · 
1 min read
Press Releases
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 4, 2024
 · 
1 min read
Press Releases
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
October 30, 2024
 · 
1 min read
News
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
October 21, 2024
 · 
1 min read
Press Releases
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
October 17, 2024
 · 
7 min read
Press Releases
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2024
October 3, 2024
 · 
1 min read
Load More